Axitinib versus sorafenib as first‑line therapy in patients with metastatic renal cell carcinoma (mRCC). This is an ASCO Meeting Abstract from the 2013 Genitourinary Cancers Symposium. This abstract ...

Open-label phase II trial of everolimus monotherapy in treatment-naive patients with advanced papillary renal cell carcinoma. Background: Axitinib is a potent, selective inhibitor of VEGFRs 1, 2, 3 ...

LIVONIA, Mich.--(BUSINESS WIRE)--Hygieia, a digital therapeutics company for insulin therapy, announces the American Medical Association (AMA) CPT Editorial Panel has approved two new Category III ...

ANN ARBOR, MI (May 9, 2012): Newly published results from a clinical study of the Diabetes Insulin Guidance System (DIGS™), under development by Hygieia, Inc., demonstrate DIGS' potential to improve ...

In this study, Italian investigators evaluated how sacubitril/valsartan (Sac/Val) dose titration among older patients with heart failure with reduced ejection fraction (HFrEF) might affect reverse ...

Dosing Enhancements May Improve Treatment Experience for Patients Receiving AVONEX® (interferon beta-1a) for Multiple Sclerosis WESTON, Mass.--(BUSINESS WIRE)--Today Biogen Idec (NASDAQ: BIIB) ...

AVONEX PEN (interferon beta-1a) 30mcg/0.5mL solution for injection by Biogen Idec Biogen Idec has received approval from the FDA for Avonex Pen (30mcg/0.5mL solution for injection) for patients ...